Brainlab, a German medical technology company, is planning an IPO on the Frankfurt Stock Exchange to raise up to €200 million. The company aims to expand into new clinical fields and enhance its digital health platform. Known for software supporting surgeries and tumor radiation therapies, Brainlab serves about 4,000 healthcare institutions across 120 countries. In the first half of fiscal 2024/25, it reported €239 million in revenue with a 22.4% operating profit margin. Founder Stefan Vilsmeier recently stepped down from daily operations but remains a long-term investor. Major banks including Berenberg and Deutsche Bank are managing the IPO, which will be conducted on Frankfurt's regulated Prime Standard market.